Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Corvus Pharmaceuticals Inc CRVS

Healthcare Biotechnology
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in... see more

Recent & Breaking News (NDAQ:CRVS)

Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

GlobeNewswire March 1, 2018

Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum

GlobeNewswire February 1, 2018

Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection

GlobeNewswire November 11, 2017

Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update

GlobeNewswire November 2, 2017

Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

GlobeNewswire October 18, 2017

Corvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 20, 2017

Corvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 11, 2017

Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

GlobeNewswire August 3, 2017

Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology

GlobeNewswire July 6, 2017

Corvus Pharmaceuticals Announces Interim Results Demonstrating Anti-Tumor Activity of CPI-444 in Renal and Lung Cancer Patients Resistant or Refractory to Prior PD-(L)1 Treatment

GlobeNewswire June 5, 2017

Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 in Renal and Lung Cancer at 2017 ASCO Annual Meeting

GlobeNewswire May 15, 2017

Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program

GlobeNewswire May 9, 2017

Corvus Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update

GlobeNewswire May 4, 2017

Corvus Pharmaceuticals Expands CPI-444 Clinical Collaboration with Genentech

GlobeNewswire May 2, 2017

Corvus Pharmaceuticals Announces Interim Results from Ongoing Phase 1/1b Study Demonstrating Safety and Clinical Activity of Lead Checkpoint Inhibitor CPI-444 in Patients with Advanced Cancers

GlobeNewswire April 4, 2017

Corvus Pharmaceuticals to Present Data That Advances the Understanding of the Adenosine Pathway in Immuno-Oncology, including New Clinical Data on CPI-444 at AACR 2017

GlobeNewswire March 20, 2017

Corvus Pharmaceuticals to Reschedule R&D Day Due to Severe Winter Storm in the New York Tri-State Area

GlobeNewswire March 13, 2017

Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

GlobeNewswire March 10, 2017

Corvus Pharmaceuticals to Host R&D Day Highlighting the Role of the Adenosine Pathway in Immuno-Oncology

GlobeNewswire March 9, 2017

Corvus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference 2017

GlobeNewswire February 27, 2017